Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke

@article{Kapil2017AntiplateletAA,
  title={Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke},
  author={Nikhil Kapil and Yvonne H. Datta and Naila Alakbarova and Eric M Bershad and Magdy H. Selim and David S. Liebeskind and Ornina Bachour and Gundu H. R. Rao and Afshin A. Divani},
  journal={Clinical and Applied Thrombosis/Hemostasis},
  year={2017},
  volume={23},
  pages={301 - 318}
}
Ischemic stroke represents one of the leading causes of death and disability in both the United States and abroad, particularly for patients with prior ischemic stroke or transient ischemic attack (TIA). A quintessential aspect of secondary stroke prevention is the use of different pharmacological agents, mainly antiplatelets and anticoagulants. Antiplatelets and anticoagulants exhibit their effect by blocking the activation pathways of platelets and the coagulation cascade, respectively… 

Figures and Tables from this paper

Indications and Evidence for Dual Antiplatelet Therapy After Acute Ischemic Stroke
TLDR
This review focuses on antiplatelet medications available in the United States with the aim to provide a summary of the available literature on poststroke dual antiplatelets therapy, pharmacological nuances of the agents, and reversal ofAntiplatelets in the setting of intracerebral hemorrhage.
Antithrombotic Therapy in the Prevention of Stroke
TLDR
There is an increasing array of approaches in an effort to provide optimal management of antithrombotic therapy, including in combination with anticoagulant therapy with the general caveat that “one size does not fit all”.
Secondary prevention in minor ischemic stroke with antiplatelet treatment. Systematic review and meta-analysis of comparative studies with aspirin under non-inferiority criteria
TLDR
A clinical superiority in the risk reduction for recurrent ischemic stroke of any antiplatelet treatment versus aspirin alone was observed, although in some instances equivalence was demonstrated.
The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis
  • Jia Yu, Wei Fang, Xin Jin
  • Medicine, Psychology
    Computational and mathematical methods in medicine
  • 2021
TLDR
Clopidogrel bisulfate tablets combined with olmesartan medoxomil has prominent clinical effects in the treatment of ischemic stroke patients with hypertension, evidently improving the prognosis and the level of AT1R may be a vital factor affecting the prog outlook.
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
TLDR
Overall, a moderate signal of higher frequency of reporting hemorrhage in rivaroxban compared with dabigatran is found and decreased hemorrhagic event reporting in apixaban compared with jabigatan is found.
Apixaban: Alternative Anticoagulation for HeartMate 3 Ventricular Assist Device
TLDR
Apixaban may be a safe alternative anticoagulant therapy in HM 3 LVAD patients, and the adverse events of bleeding, stroke, and death were similar in HM3 patients receiving warfarin or apixaban.
Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
  • J. Sokol, F. Nehaj, J. Staško
  • Medicine
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2020
TLDR
The thrombin-induced platelet aggregation is reduced in non-valvular AF patients receiving edoxaban, and there was no apparent heterogeneity across the prespecified subgroups.
Evaluation of stroke related risk factors in wake up and non-wake up stroke patients
TLDR
No significant differences were found between patients from both groups regarding stroke risk factors, however, hypertension and family history were more common in patients with WUS (p>0.05) than in non-WUS counterparts.
...
...

References

SHOWING 1-10 OF 113 REFERENCES
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
TLDR
Over two years, a multicenter, double-blind, randomized trial found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage.
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events
TLDR
Three antiplatelet regimens have demonstrated substantial reductions in secondary event risk and are currently recommended by consensus panels: aspirin monotherapy at 50–325 mg/day; the combination of aspirin plus extended-release dipyridamole (ER-DP); and clopidogrel monotherapy.
The PRoFESS trial: future impact on secondary stroke prevention
  • H. Diener
  • Medicine
    Expert review of neurotherapeutics
  • 2007
TLDR
The ongoing Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial is designed to evaluate whether extended-release dipyridamole plus aspirin compared with clopidogrel, and whether telmisartan in addition to usual care, in individuals after a stroke, will reduce the risk of further strokes.
Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.
TLDR
Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke.
The Effectiveness of Dual Antiplatelet Treatment in Acute Ischemic Stroke Patients with Intracranial Arterial Stenosis: A Subgroup Analysis of CLAIR Study
  • Xin Wang, Wenhua Lin, K. Wong
  • Medicine
    International journal of stroke : official journal of the International Stroke Society
  • 2013
TLDR
Dual treatment with clopidogrel and aspirin for seven-days is more effective than aspirin alone to reduce microembolic signals in patients with intracranial arterial stenosis.
Dabigatran Etexilate: A New Oral Thrombin Inhibitor
TLDR
The quality of anticoagulant control is frequently suboptimal among those who receive the treatment, and many patients at risk of thromboembolism do not receive treatment; only 50% to 70% of patients with atrial fibrillation who are eligible for anticoAGulant therapy are treated with a vitamin K antagonist.
Direct thrombin inhibitors.
  • C. Lee, J. Ansell
  • Medicine, Biology
    British journal of clinical pharmacology
  • 2011
TLDR
Of the new oral DTIs, dabigatran etexilate is the most studied and promising of these agents and future directions in anticoagulant therapy are discussed.
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis
TLDR
Warfarin was associated with significantly higher rates of adverse events and provided no benefit over aspirin in this trial, and aspirin should be use d in preference to warfarin for patients with intracranial arterial stenosis.
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
TLDR
Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase therisk of bleeding and death.
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
TLDR
A 600 mg clopidogrel bolus prior to initiating regular dose clopIDogrel in the setting of acute ischemic stroke was safe and the potential for risk reduction in early recurrent stroke needs to be studied in future studies.
...
...